Cancer drug Cu-64 DOTA-trastuzumab and PET imaging show promise in detecting breast cancer metastases that express the HER2 receptor, according to a study in the Journal of Nuclear Medicine. Researchers said the agent also flagged primary tumors and was able to cross the blood-brain barrier, allowing assessment of brain lesions. The data could be used to guide treatment decisions, researchers said.

Related Summaries